Clinical Trial

A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a phase 1, multicenter, open-label, first-in-human study of YL202 conducted in the United States and China. The study will evaluate the safety and tolerability of YL202 in patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated NSCLC or hormone receptor (HR)-positive and HER2-negative BC, which have been heavily treated by standard treatment.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2022-12-14; most recent amendment 2026-05-13.
Status change: Recruiting → Active, Not Recruiting 2025-08-25
Status change: Active, Not Recruiting → Recruiting 2024-09-23
Status change: Recruiting → Active, Not Recruiting 2024-06-19
Trial Details
NCT Number NCT05653752
Lead Sponsor MediLink Therapeutics (Suzhou) Co., Ltd.
Collaborators: BioNTech SE
Conditions Non Small Cell Lung Cancer, Breast Cancer
Enrollment 80 participants
Start Date 2022-12-20
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-15